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OBJECTIVE — To determine the within-trial cost-efﬁcacy of surgical therapy relative to
conventional therapy for achieving remission of recently diagnosed type 2 diabetes in class I and
II obese patients.
RESEARCH DESIGN AND METHODS — Efﬁcacy results were derived from a 2-year
randomized controlled trial. A health sector perspective was adopted, and within-trial interven-
tion costs included gastric banding surgery, mitigation of complications, outpatient medical
consultations, medical investigations, pathology, weight loss therapies, and medication. Re-
source use was measured based on data drawn from a trial database and patient medical records
andvaluedbasedonprivatehospitalcostsandgovernmentschedulesin2006Australiandollars
(AUD). An incremental cost-effectiveness analysis was undertaken.
RESULTS — Mean 2-year intervention costs per patient were 13,400 AUD for surgical ther-
apy and 3,400 AUD for conventional therapy, with laparoscopic adjustable gastric band (LAGB)
surgery accounting for 85% of the difference. Outpatient medical consultation costs were three
times higher for surgical patients, whereas medication costs were 1.5 times higher for conven-
tional patients. The cost differences were primarily in the ﬁrst 6 months of the trial. Relative to
conventional therapy, the incremental cost-effectiveness ratio for surgical therapy was 16,600
AUD per case of diabetes remitted (currency exchange: 1 AUD  0.74 USD).
CONCLUSIONS — Surgical therapy appears to be a cost-effective option for managing type
2 diabetes in class I and II obese patients.
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O
besity and type 2 diabetes are pre-
dictedtobetwoofthegreatestpub-
lic health problems of the coming
decades globally (1). The two conditions
are strongly linked (2), with weight con-
trol forming perhaps the most important
component of type 2 diabetes manage-
ment (3). Currently available lifestyle and
pharmacological strategies only provide
modest levels of weight loss for obese pa-
tients with type 2 diabetes (4–6). These
patients incur lifelong and escalating di-
rect health care costs estimated at 5,018
AUD annually in Australia (7) in 2006
and6,600USDannuallyintheU.S.(8)in
2007.
Todate,weightlosssurgeryhasfailed
to receive attention in clinical guidelines
forthemanagementoftype2diabetes(9).
One key concern has been described as
uncertainty regarding its cost-effective-
ness. Economic evaluation is uniquely
placed to analyze the tradeoffs between
the high upfront costs of weight loss sur-
gery, its strong effectiveness results, and
its potential to save future health care
treatment costs. A recent randomized
controlledtrial(RCT)conﬁrmedobserva-
tional evidence (10–13) that surgically
inducedweightlossleadstotheremission
of type 2 diabetes in the majority of obese
patients (14).
This economic evaluation sources
data directly from the trial to determine,
for the ﬁrst time, the within-trial cost-
efﬁcacy of surgically induced weight loss
relativetoconventionaltherapyforremit-
ting type 2 diabetes in obese patients.
RESEARCH DESIGN AND
METHODS— A health sector per-
spective was adopted for the economic
evaluation, comprising direct health care
coststogovernment,privateinsurers,and
patients. An incremental cost-effective-
ness analysis was undertaken, wherein
the net costs and net efﬁcacy of surgical
therapy as compared with conventional
therapy were calculated and expressed as
an incremental cost-effectiveness ratio
(ICER). The ICER was expressed as the
cost per case of type 2 diabetes remitted.
Trial design and clinical results
A 2-year RCT involving 60 obese partici-
pants (BMI 30 and 40 kg/m
2) was
conducted in Australia. It compared sur-
gically induced loss of weight with con-
ventional medical therapy (weight loss
and behavior change) for the manage-
ment of recently diagnosed (2 years)
type 2 diabetes. All patients had previ-
ously attempted to lose weight and were
involved in a 3-month run-in period
where a consulting endocrinologist rec-
ommended changes to optimize current
diabetes management. Patients were then
randomly assigned to the (unblinded) in-
terventions. There were no statistically
signiﬁcantdifferencesindemographicsor
valuescontributingtostudyoutcomesbe-
tween the two groups at baseline.
Conventional therapy reﬂected the
best available medical management. It
comprised consultation with a general
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ucator at least once every 6 weeks; medi-
cal therapies as determined by an
experienced endocrinologist specializing
in diabetes; and lifestyle modiﬁcation
programstoreduceenergyintakeanden-
courage physical activity. In addition to
all aspects of conventional therapy, surgi-
cal therapy involved the placement of a
laparoscopic adjustable gastric band
(LAGB) (LAP-BAND System; Allergan
Health, Irvine, CA) by an experienced
surgeonandassociatedovernighthospital
stay. Patient progress was reviewed by a
member of the bariatric surgical team ev-
ery 4–6 weeks, and adjustments to band
volumeweremadeusingstandardclinical
criteria.
One surgical patient withdrew from
the trial before surgery, and four medical
patients withdrew during the ﬁrst four
months of the trial. Analysis was per-
formed on an intention-to-treat basis. At
the end of the 2-year trial period, remis-
sion of diabetes (deﬁned as fasting glu-
cose 126 mg/dl and A1C 6.2% while
takingnoglycemictherapy)wasachieved
by 22 of 30 (73%) surgical patients and 4
of 30 (13%) conventional therapy pa-
tients. Full details of the trial and efﬁcacy
results have been published previously
(14).
Costs included
Trial intervention costs were included as
follows: LAGB surgery, mitigation of sur-
gical complications, outpatient medical
consultations (surgeon/physician [in-
cluding for lap-band adjustments], general
practitioner, endocrinologist, respiratory
physician, and dietitian), pathology,
medical investigations, weight loss
assistance therapies (sibutramine and op-
tifast), and medication (diabetes, antihy-
pertensives, lipids, and other).
Measurement of costs
LAGB surgery resource use was docu-
mented on patient case record forms by
hospital clinical staff. Procedures to miti-
gate surgical complications were re-
corded in patient case ﬁles. Clinical staff
recordeddatesanddescriptionsofallout-
patient medical consultations, pathology
tests, and medical investigations into a
trial database. A research nurse inter-
viewed patients every 6 months during
thetrialtodocumentutilizationofweight
loss assistance therapies and medication
by type, dosage, and frequency. Six-
month medication point estimates were
assumed to be representative of medica-
tion use during the previous 6-month pe-
riod. Actual pharmaceutical expenditure
data held by the Australian government
was accessed for all consenting patients
(23 surgical and 17 medical) to validate
medication costs.
Valuation of costs
LAGB surgery costs were sourced from a
private hospital and private medical spe-
cialists to reﬂect the private provision of
surgery, as is most common for LAGB in
Australia. Lap-band prosthesis and
weight loss assistance therapies were val-
ued based on commercial prices. Unit
costs for all other intervention resources
were obtained from pricing schedules of
the Australian government including the
Medicare Beneﬁts Schedule (MBS) (15)
and Pharmaceutical Beneﬁts Schedule
(PBS) (16). Unit costs were applied to the
resource measurements to obtain total
costs per intervention arm of the study
overthetrialperiod.Allcostsarereported
in 2006 AUD (Table 1). Costs sourced
Table 1—Intervention costs and sources
Inclusions Unit Cost (AUD) Source
LAGB surgery Specialist medical personnel (surgeon,
surgical assistant, or anesthetist)
Surgical procedure 3,000 Private medical specialist
Hospital personnel costs Surgical procedure 903 Private hospital
LAGB prosthesis Surgical procedure 3,264 Private hospital
Theater supplies, nontheater supplies,
and other expenses
Surgical procedure 1,654 Private hospital
Mitigation of surgical complications Lap-band removal and replacement Complication episode 8,821 Same as LAGB surgery
Hospital admission due to port
infection (4-day admission)
Complication episode 2,780 Public hospital
Lap-band removal Complication episode 5,557 Same as LAGB surgery
minus prosthesis
Outpatient medical consultations Surgeon/physician Consultation 32.10 MBS item 23
Surgeon/physician plus lap-band
adjustment
Consultation 118.60 MBS items 23 & 14215
Respiratory physician Consultation 37.95 MBS item 105
Endocrinologist Consultation 37.95 MBS item 106
Dietitian Consultation 40.00 Dieticians Association of
Australia
Outpatient medical pathology tests * Test * MBS (various)
Outpatient medical investigations Barium meal Investigation 89.95 MBS item 58909
Sleep study Investigation 519.60 MBS item 12203
Ophthalmic assessments Investigation 75.60 MBS item 104
Weight loss assistance therapies Optifast 1 month of use 50 Commercial pharmacy
Sibutramine 1 month of use 70 Commercial pharmacy
Medication † 6 months of use † PBS (various)
*Not described due to extensive detail (included 13 pathology tests). †Not described due to extensive detail (included 83 medications/dose speciﬁcations across the
categories of antihypertensives, diabetes, lipids, and other). MBS, Medicare Beneﬁts Schedule; PBS, Pharmaceutical Beneﬁts Schedule.
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2006valuesbyapplyingtherelevantAus-
tralian Institute of Health and Welfare
health price deﬂators (17). The midyear
2006 currency exchange rate was 1 AUD
to 0.74 USD according to XE currency
exchange (http://www.xe.com).
Analysis
Diabetes-related outcomes were deﬁned
as in the RCT as the number of cases of
diabetes remitted at 2-year follow-up.
Costs reﬂect the interventions as imple-
mented in the trial. Analysis of costs and
outcomes was performed over a 2-year
time horizon and on an intention-to-treat
basis. Intervention costs were calculated
(for patients who withdrew from the
study) up to the point of exit and most
recently collected diabetes status was as-
sumed for the remainder of the trial. No
discounting was applied to costs and out-
comes. All calculations were performed
using exact values. Results in the abstract
and text were rounded to the nearest 100
AUD, and results in tables were rounded
to the nearest 1 AUD.
RESULTS
Intervention resource use
Table 2 summarizes the mean resource
use per patient by the intervention group.
A mean resource-use value 1 indicates
that the cost was not applicable to all pa-
tients (for example, only 4 of 30 patients
experienced postoperative complica-
tions). Pathology (16 tests) and medica-
tion (83 categories) were measured in
detail but excluded from the table due to
extensive detail. Pharmaceutical expendi-
ture data held by the Australian govern-
ment for 23 surgical and 16 medical
patients were very similar to the self-
reported data for the complete samples
utilized in the analysis.
Intervention costs
The total intervention cost per group of
30patientswas401,500AUDforsurgical
therapy and 101,900 AUD for medical
therapy.Table2showsthemeancostsper
patient by resource category and inter-
ventiongroup.Surgicalcostsarebasedon
mean hospital admission and operating
theater times of 1.28 days and 54 min,
respectively. Surgical therapy was signiﬁ-
cantly more resource intensive than con-
ventional therapy, costing an additional
10,000 AUD per patient over 2 years.
LAGB surgery accounted for 85% of this
difference. Mean outpatient medical con-
sultation costs were three times higher
among surgical patients due to a greater
number of consultations (mean number
of consultations: 25 for surgical patients
and 15 for conventional therapy patients)
and higher consultation fees due to lap-
band adjustments. Mean medication
costs were 1.5 times higher for conven-
tional patients, primarily due to greater
use of diabetes medication (mean medi-
cation cost: 900 AUD per surgical patient
and 1,400 AUD per conventional therapy
patient).
Costs over time
During the ﬁrst 6 months of the trial,
mean intervention costs per patient were
approximately sevenfold greater for sur-
gical patients (10,500 AUD) than for con-
ventional therapy patients (1,400 AUD).
Table 2—Observed mean resource use per patient and costs by intervention group over the 2-year trial period
Inclusions
Mean resource use per
patient Mean cost per patient (AUD)
Surgical Conventional Surgical Conventional Difference
LAGB surgery (private hospital) Specialist medical personnel (surgeon,
surgical assistant, or anesthetist)
0.97 — 8,527 0 8,527
Hospital personnel costs 0.97 —
LAGB prosthesis 0.97 —
Theater supplies, nontheater supplies,
and other expenses
0.97 —
Mitigation of surgical complications Lap-band removal and replacement 0.07 — 866 0 866
Hospital admission due to port
infection
0.03 —
Lap-band removal 0.03 —
Outpatient medical consultations Surgeon/physician 11.60 10.93 1,727 511 1,216
Surgeon/physician plus lap-band
adjustment
10.27 0.00
Respiratory physician 0.43 0.10
Endocrinologist 2.93 3.67
Dietitian 0.23 0.43
Outpatient medical pathology tests Not described * * 632 632 0
Outpatient medical investigations Barium meal 1.00 — 690 702 12
Sleep study 1.03 1.20
Ophthalmic assessments 0.83 1.03
Weight loss assistance therapies Optifast (per month) — 1.60 0 113 113
Sibutramine (per month) — 0.47
Medication † † † 942 1,439 498
Total 13,383 3,396 9,987
*Notprovidedduetoextensivedetail(pathologyusewasequivalentinbothgroups).†Notprovidedduetoextensivedetail(costsforthesurgicaltherapygroupwere
13, 83, 86, and 194% relative to the conventional therapy group for diabetes, lipids, antihypertensives, and other medications, respectively).
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tervention group decreased with each
subsequent 6-month period until the last
6 months of the trial, when intervention
costswereequivalentinbothgroups(Fig.
1). Over time, mean 6-month medication
costs per surgical patient decreased by
more than one-half (Fig. 2).
Cost-efﬁcacy
Relative to conventional therapy, surgical
therapy facilitated remission of an addi-
tional 18 cases of type 2 diabetes at an
additional cost of 299,600 AUD, equiva-
lent to (an additional) 16,600 AUD per
(additional) case of diabetes remitted.
CONCLUSIONS — This economic
evaluation of options for managing type 2
diabetes in obese patients was based di-
rectly on data drawn from an RCT. The
data are therefore less prone to the types
of bias and uncertainty that are likely to
affect a modeled study. The results sug-
gestthatforadecisionmakerinterestedin
the immediate future (a time horizon of 2
years)anadditional16,600AUDofdirect
health care investment is required to re-
mit an additional case of recently diag-
nosed type 2 diabetes through surgically
induced weight loss.
The cost per case of diabetes remitted
is not a metric commonly utilized by de-
cision makers. The comparable ICER for
conventional therapy relative to no inter-
vention (no costs and no beneﬁts) over
the same time horizon is 25,500 AUD per
case of diabetes remitted. Therefore, the
ICER for surgical therapy (relative to con-
ventional therapy, 16,600 USD) is lower
than the comparable ﬁgure for conven-
tionaltherapy(relativetonointervention,
25,500 USD). This suggests that within a
2-year time horizon the surgical therapy
program is below the currently accepted
cost-effectiveness threshold.
The analysis provides an estimate of
just one beneﬁt: the remission of type 2
diabetes. We have not attempted to cap-
ture health care savings associated with
the reduction of other obesity-related
morbidities or the improvements of qual-
ityoflifeassociatedwithweightloss.Fur-
thermore, the outcome measure (cases of
diabetes remitted) does not capture the
substantial improvements in glycemic
control demonstrated by the surgical pa-
tientswhodidnotachievediabetesremis-
sion.Therefore,resultsunderestimatethe
cost-efﬁcacy of surgical therapy.
The key strength of this analysis (the
use of observed, within-trial cost and ef-
ﬁcacy data) is also one of its limitations. It
restricts the analysis to a 2-year time ho-
rizon, which may limit the relevance of
results to government policy makers in-
terested in long-term intervention costs,
health care system savings due to disease
prevention, quality-of-life gains, and
mortality gains. Our next study uses this
cost-efﬁcacyanalysisasthebasistomodel
these variables and reports the lifetime
cost per quality-adjusted life-year for sur-
gical therapy relative to conventional
therapy trial populations. Modeling cost-
effectiveness over a longer time period is
particularly important for this study be-
causeofthelikelydifferentialpathwaysin
medium-term weight loss and associated
diabetes remission across intervention
groups (18,19) and because our analysis
indicated that the cost differential be-
tween the intervention and control group
decreased with time.
Thegeneralizabilityofresultstoother
populations may be limited due to differ-
ent intervention effects and complication
rates (for example, due to variable exper-
tise of surgical teams) or health care costs
(whichmayvaryacrosscountries).Asdis-
cussed in an editorial of the Journal of the
American Medical Association regarding
the original RCT (20), the trial was not
powered to detect low-probability events
including postoperative mortality (21).
However, there is evidence to show that
the trial results (zero operative mortality)
have been replicated under nontrial con-
ditions (22). Data are not available re-
garding the average resource use of LAGB
patients in other parts of the world. The
trend toward shorter stays under out-
patient LAGB in the U.S. suggests that the
Australian costs may be relatively high. In
conclusion, from an economic perspec-
tive, surgically induced weight loss ap-
pears to be a cost-effective intervention
for managing recently diagnosed type 2
diabetes in obese patients.
Figure 1—Mean total intervention cost over time by intervention group.
Figure 2—Mean medication cost per patient over time by intervention group.
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